Health and economic impact of the seasonal influenza vaccination programme in England

Vaccine ◽  
2012 ◽  
Vol 30 (23) ◽  
pp. 3459-3462 ◽  
Author(s):  
Marc Baguelin ◽  
Mark Jit ◽  
Elizabeth Miller ◽  
William John Edmunds
BMJ Open ◽  
2020 ◽  
Vol 10 (2) ◽  
pp. e031851 ◽  
Author(s):  
Peter Jacoby ◽  
Catherine Glover ◽  
Chloe Damon ◽  
Parveen Fathima ◽  
Alexis Pillsbury ◽  
...  

ObjectivesTo determine how soon after commencement of the seasonal influenza vaccination programme, the AusVaxSafety active vaccine safety surveillance system, currently in use across Australia, would have detected a safety signal had it been operating in 2010 when there was an unprecedented number of febrile seizures in young children associated with one specific influenza vaccine brand, Fluvax (CSL Biotherapies).DesignSimulation study.SettingWestern Australian vaccine influenza coverage and adverse event surveillance data.Outcome measuresSimulated solicited responses from caregivers who would have received an SMS survey about adverse events experienced following seasonal influenza vaccination of their children aged 6 months to <5 years.ParticipantsNone.ResultsWe estimated a >90% probability of a safety signal being detected by AusVaxSafety based on solicited reports for either fever or medical attendance at or before the week ending 28 March 2010, 3 weeks after the start of vaccine distribution. Suspension of the national paediatric influenza vaccination programme as a result of the passive adverse events surveillance operating at the time did not occur until 23 April 2010.ConclusionsActive vaccine safety surveillance leading to rapid detection of a safety signal would likely have resulted in earlier suspension of Fluvax from the vaccination programme, prevention of many febrile convulsions and maintenance of public confidence in influenza vaccination for young children.


Vaccine ◽  
2021 ◽  
Vol 39 (2) ◽  
pp. 412-422 ◽  
Author(s):  
Ijeoma Edoka ◽  
Ciaran Kohli-Lynch ◽  
Heather Fraser ◽  
Karen Hofman ◽  
Stefano Tempia ◽  
...  

2008 ◽  
Vol 13 (51) ◽  
Author(s):  
R G Pebody ◽  
F Begum ◽  
P Gates ◽  
K Noakes ◽  
D Salisbury

For several years, the Health Protection Agency on behalf of Department of Health has undertaken routine annual uptake monitoring of the seasonal influenza vaccination programme in England in order to provide an annual estimate of uptake in targeted groups. In 2007-8, 95% of 8,375 GP practices in England took part in data collection. The national mean uptake in those 65 years and above in England was 74%, approaching the WHO target of 75%.


2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Ausenda Machado ◽  
Irina Kislaya ◽  
Amparo Larrauri ◽  
Carlos Matias Dias ◽  
Baltazar Nunes

Abstract Background All aged individuals with a chronic condition and those with 65 and more years are at increased risk of severe influenza post-infection complications. There is limited research on cases averted by the yearly vaccination programs in high-risk individuals. The objective was to estimate the impact of trivalent seasonal influenza vaccination on averted hospitalizations and death among the high-risk population in Portugal. Methods The impact of trivalent seasonal influenza vaccination was estimated using vaccine coverage, vaccine effectiveness and the number of influenza-related hospitalizations and deaths. The number of averted events (NAE), prevented fraction (PF) and number needed to vaccinate (NVN) were estimated for seasons 2014/15 to 2016/17. Results The vaccination strategy averted on average approximately 1833 hospitalizations and 383 deaths per season. Highest NAE was observed in the ≥65 years population (85% of hospitalizations and 95% deaths) and in the 2016/17 season (1957 hospitalizations and 439 deaths). On average, seasonal vaccination prevented 21% of hospitalizations in the population aged 65 and more, and 18.5% in the population with chronic conditions. The vaccination also prevented 29% and 19.5% of deaths in each group of the high-risk population. It would be needed to vaccinate 3360 high-risk individuals, to prevent one hospitalization and 60,471 high-risk individuals to prevent one death. Conclusion The yearly influenza vaccination campaigns had a sustained positive benefit for the high-risk population, reducing hospitalizations and deaths. These results can support public health plans toward increased vaccine coverage in high-risk groups.


2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Christelle Elias ◽  
Anna Fournier ◽  
Anca Vasiliu ◽  
Nicolas Beix ◽  
Rémi Demillac ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document